These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8650871)

  • 21. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
    Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
    Moinpour CM; Savage MJ; Troxel A; Lovato LC; Eisenberger M; Veith RW; Higgins B; Skeel R; Yee M; Blumenstein BA; Crawford ED; Meyskens FL
    J Natl Cancer Inst; 1998 Oct; 90(20):1537-44. PubMed ID: 9790546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
    Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
    Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
    Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
    J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate specific antigen in black and white men after hormonal therapies for prostate cancer.
    Fowler JE; Bigler SA; Renfroe DL; Dabagia MD
    J Urol; 1997 Jul; 158(1):150-4. PubMed ID: 9186343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

  • 29. Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer.
    Soloway MS; Hachiya T; Civantos F; Murphy WM; Gomez CC; Ruiz HE
    Urology; 1994 Feb; 43(2 Suppl):52-6. PubMed ID: 7509535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
    Okegawa T; Nutahara K; Higashihara E
    Int J Urol; 2010 Nov; 17(11):950-5. PubMed ID: 20807265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring--A one year follow-up.
    Lee F; Bahn DK; McHugh TA; Kumar AA; Badalament RA
    Anticancer Res; 1997; 17(3A):1511-5. PubMed ID: 9179188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
    Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE
    Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy.
    Hirano D; Hasegawa R; Satoh K; Mochida J; Yamanaka Y; Hirakata H; Yamaguchi K; Sugimoto S; Kawata N; Takahashi S
    Scand J Urol; 2014 Oct; 48(5):436-44. PubMed ID: 24730473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy.
    Gao X; Zhou T; Tang YJ; Lu X; Sun YH
    Asian J Androl; 2009 Jan; 11(1):127-30. PubMed ID: 19050694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
    Labrie F; Candas B; Gomez JL; Cusan L
    Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial.
    Zalcberg JR; Raghaven D; Marshall V; Thompson PJ
    Br J Urol; 1996 Jun; 77(6):865-9. PubMed ID: 8705223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.
    Zelefsky MJ; Lyass O; Fuks Z; Wolfe T; Burman C; Ling CC; Leibel SA
    J Clin Oncol; 1998 Oct; 16(10):3380-5. PubMed ID: 9779716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
    D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
    J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.